Forbes | Safeguarding And Streamlining Pharma Supply Chain: Time For Mandating Certified Drugs

Forbes released an article titled, "Safeguarding And Streamlining Pharma Supply Chain: Time For Mandating Certified Drugs," which highlights our discovery of another cancer-causing chemical solvent, dimethylformamide, in widely prescribed blood-pressure pills. This solvent was discovered in the drug Valsartan made by several companies, including in those made by Swiss pharmaceutical giant Novartis AG.

Real the full article via Forbes here.

Forbes | Safeguarding And Streamlining Pharma Supply Chain: Time For Mandating Certified Drugs

May 7, 2020

Forbes released an article titled, "Safeguarding And Streamlining Pharma Supply Chain: Time For Mandating Certified Drugs," which highlights our discovery of another cancer-causing chemical solvent, dimethylformamide, in widely prescribed blood-pressure pills. This solvent was discovered in the drug Valsartan made by several companies, including in those made by Swiss pharmaceutical giant Novartis AG.

Real the full article via Forbes here.

Forbes | Safeguarding And Streamlining Pharma Supply Chain: Time For Mandating Certified Drugs

Forbes released an article titled, "Safeguarding And Streamlining Pharma Supply Chain: Time For Mandating Certified Drugs," which highlights our discovery of another cancer-causing chemical solvent, dimethylformamide, in widely prescribed blood-pressure pills. This solvent was discovered in the drug Valsartan made by several companies, including in those made by Swiss pharmaceutical giant Novartis AG.

Real the full article via Forbes here.

Forbes released an article titled, "Safeguarding And Streamlining Pharma Supply Chain: Time For Mandating Certified Drugs," which highlights our discovery of another cancer-causing chemical solvent, dimethylformamide, in widely prescribed blood-pressure pills. This solvent was discovered in the drug Valsartan made by several companies, including in those made by Swiss pharmaceutical giant Novartis AG.

Real the full article via Forbes here.